Clinica Baviera S.A.
- Address
- lock Available on a paid plan
Neovascular Age‑Related Macular Degeneration (nAMD)
Clinical research at Clinica Baviera S.A. is centered on improving outcomes for patients with neovascular AMD, a leading cause of vision loss. Trials are designed to test new anti‑VEGF therapies and advanced delivery methods, aiming to preserve or restore visual acuity while reducing treatment burden.
- Evaluation of novel anti‑VEGF agents compared with standard care
- Assessment of sustained‑release delivery platforms
- Long‑term safety monitoring in real‑world settings
- Impact on best‑corrected visual acuity over multiple months
The ophthalmology department, with six investigators, is conducting eight active studies to advance treatment options for nAMD patients in Madrid.
Geographic Atrophy (GA) in Dry AMD
Several investigations focus on geographic atrophy secondary to dry age‑related macular degeneration, exploring gene‑based therapies and long‑term safety. The goal is to halt disease progression and maintain retinal health for individuals who have limited treatment choices today.
- Gene therapy approaches targeting complement pathways
- Extended safety follow‑up over several years
- Evaluation of structural retinal changes via imaging
- Patient‑reported outcomes on visual function
These studies build on earlier trials and provide valuable data for future therapeutic strategies at Clinica Baviera.
Innovative Intravitreal Delivery Platforms
The site is also evaluating cutting‑edge delivery systems such as the Port Delivery System, which aim to reduce injection frequency and improve patient convenience. Research assesses optimal refill intervals and overall device safety while measuring visual performance.
- Comparison of 24‑week versus 36‑week refill schedules
- Device‑related adverse event tracking
- Patient adherence and quality‑of‑life assessments
- Integration of sustained‑release formulations
This work complements the broader AMD program and reflects the clinic’s commitment to innovative ophthalmic care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinica Baviera S.A.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Janssen Cilag International | Phase II | Not Recruiting | Aug 2023 | Feb 2026 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ranibizumab | 3 | Unknown | 2021-10-22 | 2024-06-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.